Preliminary analysis of clinical characteristics of patients enrolled in the HD01 protocol: a randomised trial of high dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's disease responding to first line therapy.

[1]  J. Armitage,et al.  Autologous transplantation for Hodgkin's disease: coming of age? [editorial; comment] , 1994 .

[2]  D. Reece,et al.  Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. , 1994, Blood.

[3]  P. Gobbi,et al.  MOPP/EBV/CAD hybrid chemotherapy with or without limited radiotherapy in advanced or unfavorably presenting Hodgkin's disease: a report from the Italian Lymphoma Study Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  K. Propert,et al.  Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. , 1992, The New England journal of medicine.

[5]  D. Longo,et al.  Hodgkin's disease. , 1992, The New England journal of medicine.

[6]  A. Carella.  Indications for autologous bone marrow transplantation in Hodgkin's disease. , 1992, Leukemia & lymphoma.

[7]  A. Bacigalupo,et al.  Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol. , 1991, Bone marrow transplantation.

[8]  P. Donnan,et al.  A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party. , 1991, European journal of cancer.

[9]  B. Clarkson,et al.  Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Armitage.  Bone marrow transplantation in the treatment of patients with lymphoma. , 1989, Blood.

[11]  J. Gribben,et al.  Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. , 1989, Blood.

[12]  P. Mazza,et al.  High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Connors,et al.  An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV Hybrid program. , 1988, Seminars in hematology.

[14]  A. Rossi,et al.  HODGKIN'S DISEASE PROGNOSIS: A DIRECTLY PREDICTIVE EQUATION , 1988, The Lancet.

[15]  S M Hubbard,et al.  The chemotherapy of lymphomas: looking back, moving forward--the Richard and Hinda Rosenthal Foundation award lecture. , 1987, Cancer research.

[16]  P. Hervé,et al.  High dose chemotherapy and autologous bone marrow transplantation in refractory Hodgkin's disease. , 1986, British Journal of Cancer.

[17]  S. Rosenberg,et al.  A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  H. Kaplan.  Hodgkin's disease: Unfolding concepts concerning its nature, management and prognosis , 1980, Cancer.

[19]  G. Bonadonna,et al.  Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP , 1975, Cancer.